Expandi Limited and Kompass Announce Strategic Alliance to Transform B2B Marketing, Advertising and Data Solutions
26.5.2025 10:00:00 CEST | Business Wire | Press Release
Expandi Limited, Europe’s most recognized B2B MarTech and AdTech vendor and one of the leading worldwide, and Kompass, a global leader in B2B SalesTech and MarTech solutions and editor of the marketplace www.kompass.com, have entered a groundbreaking alliance. This partnership aims to redefine how businesses connect, market, and grow by leveraging cutting-edge technology and unparalleled data resources.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250526650205/en/
The agreement covers multiple strategic areas that will deliver innovative solutions to the B2B market:
Key Areas of Collaboration
- Innovative B2B Platform
The partnership will integrate Expandi's B2B Stars platform with www.Kompass.com, one of Europe’s most accurate and populated B2B marketplace. This integration will create a comprehensive "find and be found" solution, enabling companies worldwide to connect with trustworthy partners based on reliable criteria such as verified reviews, financial ratings, and industry awards. - Targeted Advertising on Kompass.com
Expandi's advanced digital advertising solutions, including AccountInsight, will be deployed on kompass.com, one of the highest-traffic B2B websites in Europe. Advertisers will benefit from precise targeting capabilities using firmographics, technographics, intent signals, location data, and more—providing unparalleled reach and relevance. Expandi is mandated by Kompass to offer the new premium placement to Expandi’s direct clients in the enterprise space and to Expandi’s network of global media agencies. - Intent Data Synergy
Expandi's Cyance multi-language intent insights platform will be enriched with Kompass's real-time business intelligence powered by AI, and Kompass generated Intent Data. This synergy will provide businesses with deeper insights into buyer behavior, enabling them to identify opportunities early in the decision-making process. - Data Integration for ABM Excellence
Expandi’s award-winning ABM platform, Jabmo, will now incorporate Kompass’s database of over 60 million companies, with smart AI generated business criteria, and 200 million contacts across 70+ countries. This integration further enhance Jabmo targeting capabilities for B2B marketers planning to reach both micro businesses and/or additional regions of the world not yet covered by the current platform. - Advanced Analytics for Business Insights
Kompass’s flagship SalesTech and MarTech solutions, including EasyBusiness, will integrate analytics from B2B Stars on over 3 million companies in the US and Europe, including the Corporate Reputation Score and AI-optimized company reports. These reports highlight strengths and weaknesses based on the world’s most comprehensive database of verified B2B reviews.
A Game-Changing Alliance
The partnership between Expandi Limited and Kompass represents a significant milestone in the evolution of B2B marketing and data-driven solutions. By combining Expandi’s expertise in MarTech and AdTech with Kompass’s unparalleled business intelligence resources, this alliance will empower businesses to achieve new levels of efficiency, precision, and growth.
This alliance is set to redefine the future of B2B marketing by delivering unmatched value through innovation, precision targeting, and actionable insights.
Raffaele Apostoliti, Founder & CEO of Expandi Limited, commented:
"This partnership is a natural fit between two leaders in their respective fields. By integrating our advanced marketing technologies with Kompass's vast global data resources and martech solutions, we are creating a unique ecosystem that will redefine how businesses connect and grow in the digital age."
Patrick Coupier, CEO at Kompass Group, added:
" Kompass has always been at the forefront of providing trusted business data for companies worldwide and smart MarTech and SalesTech SaaS solutions. This partnership marks another key step in this long tradition of innovation. By joining forces with Expandi, we’re combining our global Smart Data capabilities with cutting-edge marketing and advertising technologies to offer even more powerful, insight-driven solutions. Together, we’re redefining how businesses find, connect with, and convert their ideal B2B prospect, locally and globally”
About Expandi Limited
Expandi Limited is one of the leading worldwide providers of B2B MarTech and AdTech solutions, recently awarded as #1 Leader in ABM worldwide by Frost & Sullivan. Recognized for its innovative platforms such as Jabmo (ABM), Cyance (intent data), Accountinsight (DSP for B2B Programmatic Ad)and B2B Stars (AI powered business directory), Expandi empowers businesses to drive smarter marketing strategies through data-driven insights. Most of the Global media agencies and several of the largest B2B companies are using Expandi platforms and insights across the globe.
About Kompass
Kompass is a global B2B SalesTech and MarTech enabler, providing smart prospecting and lead generation solutions to help companies grow faster, locally and internationally. With a trusted, GDPR-compliant database of over 60 million companies,200 million contacts in 70+ countries, and more than 4 M unique visitors on its marketplace, www.Kompass.com, Kompass empowers businesses with powerful tools like EasyBusiness, KSales and targeted advertising services. From Smart Data to global visibility, Kompass is “your route to business, worldwide”.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250526650205/en/
Contacts
For media inquiries:
Expandi Limited Media Team
Email: paola.dotti@expandigroup.com
Paola Dotti
Phone: + 39 347 2832 552
Kompass Media Relations
Email: carolina.clark@kompass.com
Carolina - press@kompass.com Clark
Phone: +34 652 04 47 87
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom